Table 6.

Bioavailability (and 90% CIs) of the non-fasting regimen of ABT-288 relative to the fasting regimen (5 mg single dose)

Parameter	Central value*		Relative bioavailability
	Point estimate†	90% CIs
			Non-fasting	Fasting
Cmax (ng ml−1)	2.87	2.92	0.985	0.871, 1.114
AUC(0,tlast) (ng h ml−1)	105	100	1.042	0.995, 1.091
AUC(0,∞) (ng h ml−1)	127	124	1.022	0.960, 1.088

^*Antilogarithm of the least squares means for logarithms.

^†Antilogarithm of the difference (test − reference) of the least squares means for logarithms.